ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of Bone. by Greco, Nicholas et al.
Journal of Cancer Therapy, 2014, 5, 331-338 
Published Online April 2014 in SciRes. http://www.scirp.org/journal/jct 
http://dx.doi.org/10.4236/jct.2014.54040  
How to cite this paper: Greco, N., et al. (2014) ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of 
Bone. Journal of Cancer Therapy, 5, 331-338. http://dx.doi.org/10.4236/jct.2014.54040   
 
 
ALDH Activity Correlates with Metastatic 
Potential in Primary Sarcomas of Bone 
Nicholas Greco1,2, Trevor Schott1,2, Xiaodong Mu1,2, Adam Rothenberg1,2, Clifford Voigt1,2, 
Richard L. McGough III1,3, Mark Goodman1,3, Johnny Huard1,2,3, Kurt R. Weiss1,2,3 
1Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, USA 
2Cancer Stem Cell Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, USA 
3University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, USA 
Email: greconj2@upmc.edu  
 
Received 22 January 2014; revised 20 February 2014; accepted 27 February 2014 
 
Copyright © 2014 by authors and Scientific Research Publishing Inc. 
This work is licensed under the Creative Commons Attribution International License (CC BY). 
http://creativecommons.org/licenses/by/4.0/ 
  
 
 
 
Abstract 
Osteosarcoma (OS), chondrosarcoma (CSA), and Ewings sarcoma (ES) are the most common pri-
mary malignancies of bone, and are rare diseases. As with all sarcomas, the prognosis of these 
diseases ultimately depends on the presence of metastatic disease. Survival is therefore closely 
linked with the biology and metastatic potential of a particular bone tumor’s cells. Here we de-
scribe a significant correlation of aldehyde dehydrogenase (ALDH) activity and the presence/ab- 
sence of distant metastases in ten consecutive cases of human bone sarcomas. Additionally, cul-
tured human CSA cells, which are historically chemo- and radio-resistant, may be sensitive to the 
ALDH inhibitor, disulfiram. While it is premature to draw broad conclusions from such a small se-
ries, the importance of ALDH activity and inhibition in the metastatic potential of primary bone 
sarcomas should be investigated further. 
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1. Introduction 
Osteosarcoma (OS), chondrosarcoma (CSA) and Ewings sarcoma (ES) are the three most common primary ma-
lignancies of bone [1]-[6]. Most examples of “bone cancer” treated by musculoskeletal oncologists are cases 
wherein cancer has metastasized to the bony skeleton. Examples of primary tumors that metastasize to bone in-
clude epithelial neoplasia such as breast, prostate, renal, thyroid, and lung carcinomas [7] [8]. In contrast, pri-
mary bone sarcomas are rare diseases of mesenchymal origin that arise within the skeleton itself. As with all 
N. Greco et al. 
 
 332 
sarcomas, the prognosis of primary bone sarcoma is ultimately determined by the presence or absence of sys-
temic metastatic disease [9]-[12]. The most common site for sarcoma metastasis is to the lung, but other sites 
such as bone and lymph node also occur [13]-[18]. 
Modern treatment strategies for OS and ES include neoadjuvant chemotherapy, wide resection of the tumor, 
and post-operative chemotherapy. Unfortunately, CSA is resistant to both cytotoxic chemotherapy and external 
beam radiotherapy, and thus is primarily a surgical disease [19] [20]. Regardless of the histologic subtype, the 
metastatic potential of bone sarcoma cells dramatically impacts patient survival, as cure is much less likely in 
the setting of systemic disease. While advances in chemotherapy and surgery have improved local control and 
patient functionality, there have not been significant advances in the survival of patients with bone sarcomas in 
over two decades [13] [21] [22]. Clearly, a more complete understanding of the biology of bone sarcoma metas-
tases is required if prognoses are to improve. 
Aldehyde dehydrogenase (ALDH) is a tetrameric enzyme that oxidizes aldehydes to carboxylic acids and 
enables cells to resist oxidative stress. ALDH has been implicated as a cancer stem cell marker. Cells with high 
ALDH levels have demonstrated enhanced tumorigenicity in multiple cancer cell types. In clinical studies, high 
ALDH activity predicted poor survival in breast and ovarian cancer [23]-[29]. We observed that highly metas-
tatic murine OS cells displayed greater resistance to oxidative stress than less metastatic murine OS cells when 
challenged with H2O2, and hypothesized that diminished ALDH activity in the less metastatic cells might ex-
plain this difference. Indeed, we demonstrated and published that ALDH expression and activity are significant-
ly greater in murine OS cells with high metastatic potential than in less metastatic murine OS cells. ALDH-high 
cells were also more invasive than ALDH-low cells through a semisolid matrigel matrix. Finally, we treated OS 
cells with the ALDH inhibitor, disulfiram, and observed that disulfiram effectively reduced ALDH activity and 
altered metastatic OS cell morphology, resulting in fewer filopodia and greater uniformity of shape [15] [16]. 
These data suggested that ALDH is important to OS metastatic biology, and its inhibition in vitro caused dimi-
nished metastatic potential. 
We wished to understand the importance of ALDH in the metastatic potential of human bone sarcomas. In 
order to accomplish this, the ALDH activity of cultured human bone sarcomas cells was assayed and compared 
with the metastatic histories of the patients from whom they were derived. We also treated primary bone sarco-
ma cells with disulfiram and doxorubicin (a cytotoxic agent commonly used in the treatment of bone sarcomas), 
and evaluated their effects on human bone sarcoma cells in vitro. 
2. Materials and Methods 
2.1. UPMC Musculoskeletal Oncology Research Registry and Tissue Bank 
The University of Pittsburgh Medical Center (UPMC) Musculoskeletal Oncology Research Registry and Tissue 
Bank is an Institutional Review Board-approved data collection system wherein signed written informed consent 
from each participant allows us to collect the clinical data of patients with benign and malignant bone tumors 
prospectively from the time of diagnosis throughout the entire course of care. Additionally, patients’ tumor tis-
sue may be harvested as a reagent for laboratory study at the time of biopsy or surgery. We accrued ten consecutive 
patients with primary bone tumors whose cells had been harvested at the time of biopsy or surgery between Oc-
tober, 2011 and April, 2013. Their demographic data, histologic diagnosis, and metastatic history were evaluated. 
2.2. Establishing Bone Sarcoma Cell Lines 
Tumor tissue from patients was washed with Dulbecco’s Phosphate-Buffered Saline (DPBS), finely minced, and 
enzymatically digested at 37˚C in 0.2% collagenase-type XI (Sigma-Aldrich) for one hour. The cells were then 
incubated at 37˚C in dispase (2.4 U/ml in HBSS, Invitrogen) for 45 minutes. Cells were then washed with DPBS 
and centrifuged (2500 rpm, 5 minutes) to obtain a cell pellet, which was then resuspended in proliferation medium 
(PM-DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (all from Invi-
trogen)). The dissociated cells in PM were passed through a 100 µm filter, and inoculated into plastic tissue cul-
ture flasks. Cells were maintained at 37˚C, 5% CO2, in a humidified incubator and PM was changed every 3 days. 
2.3. ALDH Assays via Fluorescence-Activated Cell Sorting (FACS) Analysis of ALDH Activity 
The Aldelfluor Kit (STEMCELL Technologies) was used to determine the enzymatic activity of ALDH in cul-
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tured bone sarcoma cells. Human bone sarcoma cells were trypsinized, washed with DPBS, and counted using a 
hemocytometer. Cells were then resuspended in Aldefluor buffer at a concentration of 1 × 106 cells/mL. Aldef-
luor buffer contains an ABC transport inhibitor that prevents efflux of the Aldefluor dye. Cells were then incu-
bated at 37˚C for one hour, washed in Aldefluor buffer, and maintained in 4˚C throughout the process of ALDH 
assay per the manufacturer’s instructions. High ALDH activity was assessed using the FL1 channel of a BD 
FACSAria Cell Sorting System and FACSDiva software (version 6.1.2; Becton, Dickinson and Company, San 
Jose, CA). Collected cells were analyzed for high ALDH activity with fluorescence-activated cell sorting 
(FACS), according to their fluorescence intensity, which corresponds to their ALDH activity levels, as well as 
low side scatter (SCClo). 
2.4. Disulfiram Treatment 
Cultured human tumor cells were trypsinized, washed in DPBS, and counted using a hemocytometer. Cells were 
then plated in a 12-well dish (10,000 cells/well, in 1 mL of PM). Cells were allowed to adhere to the flask over-
night and treated with disulfiram at concentrations of 0, 500 nM, 1 uM, and 1.5 uM. 48 hours later, the cells 
were fixed with 4% paraformaldehyde for 10 mins. The brightfield images of the cells were taken using a Nikon 
Eclipse E800 microscope (Melville, NY) equipped with a Retiga Exi digital camera (QImaging). All images 
were acquired and analyzed using Northern Eclipse software (version 6.0; Empix Imaging). 
2.5. Doxorubicin Treatment 
Human bone sarcoma cells were evaluated for response to doxorubicin, a cytotoxic chemotherapy often used in 
the treatment of bone sarcomas. Cells were plated 50,000 cells/well in 12 well plates in proliferation medium. 
Cells were allowed to proliferate at 37 C for 24 hours. Doxorubicin was then added in varying concentrations (0, 
25 uM, 50 uM, 100 uM, 250 uM, and 500 uM) and the cells were incubated for 24 hours. At that point, cells 
were fixed in 10% formaldehyde for 5 minutes. The brightfield images of the cells were taken using a Nikon Ec-
lipse E800 microscope (Melville, NY) equipped with a Retiga Exi digital camera (QImaging). All images were 
acquired and analyzed using Northern Eclipse software (version 6.0; Empix Imaging). 
2.6. Statistical Analysis 
A student’s t test was used to calculate a p value between metastatic and non-metastatic groups. A p value of 
less than 0.05 was considered the threshold for statistical significance. Statistical analyses were performed by a 
biostatistician not directly involved with the project. 
3. Results 
3.1. Bone Sarcoma Patients and ALDH Activity 
Table 1 illustrates the age, gender, histologic diagnosis, site of metastasis (where applicable), ALDH activity of 
each patient’s cultured tumor cells, and standard deviations of the ALDH values when more than one measure-
ment was performed. There were seven males and three females and the average age of the entire cohort was 
57.4 years at the time of diagnosis. There were three cases of OS, five cases of CSA, and two cases of ES. The 
average age of the five patients with OS and EWS was 45 years, and the average age of the five CSA patients 
was 69.8 years. Of the patients who experienced metastases, 87.5% (seven of eight) experienced pulmonary 
metastases. Two patients experienced metastases to additional locations besides the lung (brain, bone) and one 
patient developed lymph node metastases. The average percentage of ALDH-high cells among the patients who 
had metastases was 18.1, and 2.1 in non-metastatic patients, with standard deviations of 12.6 and 1.3, respec-
tively. According to our statistician, the difference in the percentage of ALDH-high cells between the metastatic 
and non-metastatic patients did reach statistical significance with a p value of 0.0091. If ALDH-high percentage 
of 3.1 was used as a threshold value, high ALDH activity correlated 100% with the incidence of metastases. 
Figure 1 illustrates a sample ALDH activity assay from patient #4, a 63-year-old female with CSA metastatic 
to her lungs. 20.3% of her cells displayed high ALDH activity. Figure 2 displays the ALDH activity of patient 
#3, an 86 years old male with non-metastatic CSA. Note the difference in the percentage of ALDH-high cells, as 
depicted by the green curves. 
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Table 1. Summarizes our series of ten consecutive patients with bone sarcomas. 
Patient age Gener (M/F) Histology (OS,CSA,ES) Site of mets ALDH ALDH st dev 
70 M CSA Lung 23.2 2.7 
80 M CSA - 3.05 2.85 
86 M CSA - 1.2 - 
63 F CSA Lung 20.3 - 
19 M OS Lymph node 39.4 - 
35 M ES Lung, brian 4.5 2.6 
27 M ES Lung, bone 26.6 - 
50 M CSA Lung 21.2 - 
60 F OS Lung 3.9 - 
84 F OS Lung 5.5 - 
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Figure 1. Demonstrates the ALDH activity of patient #4, a 63 years old female with CSA metastatic to her lungs. Her per-
centage of ALDH-high cells was 20.3. The average of percentage of ALDH-high cells in patients with metastatic disease was 
18.1 (standard deviation = 12.6). 
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Figure 2. Depicts the ALDH activity of patient #2, an 86 years old male with non-metastatic CSA. His percentage of 
ALDH-high cells was 1.2. The average percentage of ALDH-high cells in non-metastatic patients was 2.1 (standard devia-
tion = 1.3). 
3.2. Disulfiram and Doxorubicin Experiments 
Both disulfiram and doxorubicin decreased bone sarcoma cell proliferation in a dose-dependent fashion 
(Figures 3-5). 
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Patient#5, 19M with OS metastic to lymph node 
control Disulfiram 
1uM 
Disulfiram 
500nM 
Disulfiram 
1.5uM 
control Dox 25 uM Dox 50 uM 
Dox 500 uM Dox 100 uM Dox 250 uM  
Figure 3. Demonstrates the response to disulfiram and doxorubicin 
(Dox) in patient #5, a 19 years old male with OS metastatic to his 
lymph nodes. Both disulfiram and doxorubicin demonstrated qualita-
tive decreases in cell proliferation). 
 
 
Patient#2, 80M with non-metastatic CSA 
control Disulfiram 
1uM 
Disulfiram 
500nM 
Disulfiram 
1.5uM 
control Dox 25 uM Dox 50 uM 
Dox 500 uM Dox 100 uM Dox 250 uM  
Figure 4. Shows the responses to disulfiram and doxorubicin (Dox) of 
patient #2, an 80 years old male with non-metastatic CSA. Both disul-
firam and doxorubicin demonstrated qualitative decreases in cell pro-
liferation. 
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Patient#4, 63F with CSA metastatic to lung 
control Disulfiram 
1uM 
Disulfiram 
500nM 
Disulfiram 
1.5uM 
control Dox 25 uM Dox 50 uM 
Dox 500 uM Dox 100 uM Dox 250 uM  
Figure 5. Displays the histology of patient #4, a 63 years old female with 
CSA metastatic to her lungs. Both disulfiram and doxorubicin (Dox) dem-
onstrated qualitative decreases in cell proliferation. 
4. Discussion 
Bone sarcomas are rare, primary skeletal neoplasia. The most common forms are OS, CSA, and ES. Like all 
sarcomas, the prognosis of these diseases is ultimately determined by the presence of metastatic disease [9]-[12]. 
Others have demonstrated that ALDH expression and activity correlates with prognosis in other neoplasia, but 
this relationship has not been thoroughly evaluated in sarcomas of bone. We have previously demonstrated in 
murine OS cells that high ALDH activity correlates with murine OS cell biology [15] [16]. Here we report on 
the level of ALDH activity in a consecutive series of bone sarcoma patients. 
This study has several limitations, not the least of which is the small series (n = 10) of bone sarcoma patients. 
While we did demonstrate a statistically significant difference (p = 0.0091) between the percentage of ALDH- 
high cells in metastatic versus non-metastatic patients, we are reluctant to draw any broad conclusions at this 
time. These data, while novel and encouraging, are very limited. Greater numbers of both metastatic and non- 
metastatic bone sarcoma patients should be studied in order to confirm or refute the hypotheses that ALDH ac-
tivity correlates with bone sarcoma metastatic potential, and that bone sarcoma cell metastatic potential can be 
affected via ALDH inhibition. 
As with our murine OS cell data, we appreciated a dose-dependent effect with disulfiram treatment. While 
this was not completely surprising in our human OS patient, it was interesting to observe this in the CSA pa-
tients as well. CSA is remarkably chemo- and radio-resistant. CSA is therefore treated with surgery alone, as 
other adjuvants do not impact upon survival. We hypothesize that the ability to withstand oxidative stress via 
high ALDH activity is an essential attribute that sarcoma cells must possess in order to metastasize throughout 
the body. The feasibility of disulfiram or other ALDH inhibitors as much-needed adjuvants in the treatment of 
CSA and other bone sarcomas must be investigated, and these experiments are under way. Additionally, the 
importance of ALDH activity vis-a-vis the metastatic potential of soft tissue sarcoma should also be evaluated 
with a similar strategy outlined above. 
5. Conclusion 
In conclusion, we have demonstrated a significant correlation between ALDH activity and metastatic potential 
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in a consecutive series of ten patients with OS, CSA, and ES. We have also demonstrated that human OS and 
CSA cells are sensitive to ALDH inhibition with disulfiram, which raises the possibility of using ALDH inhibi-
tion as a therapeutic strategy in bone sarcomas. These data are fascinating, but additional investigations are re-
quired to understand more completely the relationship between ALDH and metastatic potential in bone sarco-
mas. 
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